Takeda licenses PARP inhibitor | August 7, 2017 Issue - Vol. 95 Issue 32 | Chemical & Engineering News
Volume 95 Issue 32 | p. 13 | Concentrates
Issue Date: August 7, 2017

Takeda licenses PARP inhibitor

Department: Business
Keywords: drug development, PARP inhibitor, niriparib

Takeda is paying Tesaro $100 million up front for the rights in certain countries to the PARP inhibitor niraparib, which received FDA approval in April to treat recurrent ovarian cancer. Takeda gains broad rights to develop niraparib in Japan and to pursue the compound as a prostate cancer treatment in South Korea, Taiwan, Russia, and Australia. Tesaro could see another $240 million in milestone payments if niraparib is approved in those markets.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment